98%
921
2 minutes
20
Background: The Additional Roles Reimbursement Scheme (ARRS) was introduced in England in 2019 to alleviate workforce pressures in general practice by funding additional staff such as clinical pharmacists, paramedics, first-contact physiotherapists, and from 1 October 2024 the scheme funds recently qualified GPs. However, the employment and deployment models of ARRS staff present ongoing complexities and challenges that require further exploration.
Aim: To explore the decision-making processes behind primary care networks (PCNs) and general practice staffing choices, and how these choices influence the operationalisation of ARRS.
Design And Setting: This was a qualitative case study across four PCNs in England using a realist evaluation framework.
Method: Data collection took place between September 2022 and November 2023. Semi-structured interviews were conducted with PCN clinical directors, GPs, practice managers, and ARRS staff ( = 42). Transcripts were analysed using a realist evaluation framework to identify the context-mechanism-outcome configurations.
Results: Direct employment models fostered staff development and retention, contingent on established trust among practices. Subcontracting was favoured to mitigate employment risks but could lead to unintended consequences such as conflicting accountabilities and less integration with existing GP practice staff. The optimal deployment model involved rotations across a limited number of GP practices, ideally two, with one serving as a base, ensuring consistency in training and management.
Conclusion: This study provides novel insights into the complexities of different employment and deployment models of ARRS staff. These findings will be invaluable for creating a sustainable GP practice workforce and informing future workforce strategies as the scheme expands to include recently qualified GPs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11800407 | PMC |
http://dx.doi.org/10.3399/BJGP.2024.0562 | DOI Listing |
Vaccine
September 2025
Department of Tropical Medicine, Medical Microbiology & Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Mānoa, Honolulu, HI 96813, USA. Electronic address:
Filoviruses, including the well-known Ebola virus, are among the most lethal pathogens known. The current vaccine landscape is constrained by stringent cold chain requirements making vaccine deployment challenging, especially in regions with limited infrastructure. ERVEBO®, the sole FDA-approved filovirus vaccine, requires ultra-cold storage.
View Article and Find Full Text PDFSci Rep
August 2025
CSE, Vasavi College of Engineering, Hyderabad, Telangana, India.
AI has propelled the potential for moving toward personalized health and early prediction of diseases. Unfortunately, a significant limitation of many of these deep learning models is that they are not interpretable, restricting their clinical utility and undermining trust by clinicians. However, all existing methods are non-informative because they report generic or post-hoc explanations, and few or none support patient-specific, accurate, individualized patient-level explanations.
View Article and Find Full Text PDFJ Head Trauma Rehabil
August 2025
Author Affiliations: Center for Health Optimization and Implementation Research, VA Boston Healthcare System, Boston, Massachusetts (Dr Pogoda); Department of Health Law, Policy & Management, Boston University School of Public Health, Boston, Massachusetts (Dr Pogoda); Health Economics Resource Cent
Objective: Those who served on active duty after September 11, 2001 (Post-9/11) are screened for deployment-related mild traumatic brain injury (mTBI) when initiating Veterans Health Administration (VHA) clinical services. Positive screeners are offered a referral to a Comprehensive TBI Evaluation (CTBIE) by a TBI specialist to further determine deployment-related mTBI history and access interdisciplinary care if indicated. This study examined whether Post-9/11 veterans who screened positive and also participated in a prospective longitudinal study (PLS) differed in characteristics and outcomes depending on their clinical VHA CTBIE completion status and mTBI positive (+) or negative (-) determinations (CTBIE = mTBI+, CTBIE = mTBI-, No CTBIE).
View Article and Find Full Text PDFClin Ther
August 2025
Highlander Health, Dallas, Texas.
Despite efforts to improve research equity in clinical trials, a lack of representativeness continues to threaten the generalizability of clinical trial evidence and leads to several ethical and economic consequences. Decentralized clinical trials (DCTs) and pragmatic clinical trials (PCTs), novel clinical trial models that use technology to enable alternative data collection methods and integrate studies into clinical care, hold great promise for addressing representativeness challenges but also face several limitations. Leveraging technology and clinical care settings to conduct trial visits and collect trial data inherently limits participation from people without reliable access to technology and consistent medical care.
View Article and Find Full Text PDFComput Biol Med
September 2025
Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, De Boelelaan 1118, 1081 HV, Amsterdam, the Netherlands; Varian Medical Systems, a Siemens Heal
Background: Convolutional neural networks (CNNs) have emerged to reduce clinical resources and standardize auto-contouring of organs-at-risk (OARs). Although CNNs perform adequately for most patients, understanding when the CNN might fail is critical for effective and safe clinical deployment. However, the limitations of CNNs are poorly understood because of their black-box nature.
View Article and Find Full Text PDF